Last reviewed · How we verify

Bupivacaine 25cc

Hospital for Special Surgery, New York · FDA-approved active Small molecule Quality 2/100

Bupivacaine 25cc is a Small molecule drug developed by Hospital for Special Surgery, New York. It is currently FDA-approved. Also known as: Exparel, Marcaine, Marcaine Spinal (PF).

At a glance

Generic nameBupivacaine 25cc
Also known asExparel, Marcaine, Marcaine Spinal (PF)
SponsorHospital for Special Surgery, New York
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine 25cc

What is Bupivacaine 25cc?

Bupivacaine 25cc is a Small molecule drug developed by Hospital for Special Surgery, New York.

Who makes Bupivacaine 25cc?

Bupivacaine 25cc is developed and marketed by Hospital for Special Surgery, New York (see full Hospital for Special Surgery, New York pipeline at /company/hospital-for-special-surgery-new-york).

Is Bupivacaine 25cc also known as anything else?

Bupivacaine 25cc is also known as Exparel, Marcaine, Marcaine Spinal (PF).

What development phase is Bupivacaine 25cc in?

Bupivacaine 25cc is FDA-approved (marketed).

Related